Endovascular stenting of native aortic coarctation has become standard treatment for children and young adults due to the shorter hospital stay and recovery time, lower procedural risk and less invasive nature. However, despite these advantages, neonatal coarctation remains a surgically treated lesion, owing to the challenges of vessel growth and stent design. Plain old balloon angioplasty (POBA) of neonatal coarctation has been used as a treatment modality in the past but concern around vessel damage and aneurysm formation limited its widespread adoption. To-date, stenting has often been preferred over POBA treatment to minimise tissue damage but very little evidence has been gathered to establish the degree of tissue damage during intravascular procedures in neonatal coarctation tissue. The aim of this study was to perform balloon angioplasty and stenting on coarctation the aorta samples harvested at the time of surgery from neonatal patients and visualise the deformation under ultrasound guidance. From this, the novel collagen hybridizing peptide (CHP) was used to assess the level of collage denaturation and microstructural damage this tissue experienced when undergoing these procedures. The results demonstrate that balloon angioplasty singularly is not a viable treatment option at maintaining the lumen diameter unless higher levels of stretch are achieved to permanently deform the tissue. Five out of six neonatal coarctation samples were successfully stented with no stent failure, proving that stent insertion is a viable option to achieve the desired lumen diameter. In addition, for both procedures, increased collagen damage was observed with higher tissue strain. Overall, this work would suggest stent placement as the best option to achieve reliable lumen gain and to limit the level of the level of collagen damage when stretching the tissue to achieve the required lumen diameter.

The authors have declared no competing interest.

Research was supported by the StAR MD Program in the RCSI incorporating the Beacon Hospital, Dublin; and by a research grant from Science Foundations Ireland (SFI) under the grant number 12/RC/2278_2.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethical approval for obtaining the samples and imaging used in this study was obtained from the research and ethics board of Children's Health Ireland. Informed consent was obtained from the parents / legal guardians of all patients for the tissue samples used in this study

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors